|
National Stock Number(NSN): 6505-01-343-2105 (6505013432105, 013432105)
| NIIN: |
01-343-2105 |
Item Name: |
CEFTAZIDIME FOR INJECTION |
INC: |
42844
|
| FSC: |
6505
|
Assignment Date: |
Aug-08-1991 |
CRIT: |
N |
IIG: |
42844 |
| ISC: |
5 |
Date Standardized: |
Aug-08-1991 |
HMIC: |
P |
DODIC: |
|
| NSC: |
8 |
Cancellation Date: |
Nov-20-2002 |
PMIC: |
A |
FIIG: |
A34300 |
| ESD: |
|
Schedule B: |
|
DEMIL: |
A |
DEMIL INT: |
|
| TIIC: |
1 |
Originator: |
97 |
ADPEC: |
|
RPDMRC: |
|
| Part Number |
CAGE |
Company |
Status |
RN CC |
RN VC |
DAC |
RN AAC |
RN FC |
RN SC |
RN JC |
SADC |
HCC |
MSDS |
|
NDC00007-5086-11 |
93544
|
GLAXOSMITHKLINE HOLDINGS (AMERICAS) INC. |
H |
3 |
1 |
4 |
KX |
|
|
|
|
|
|
|
TAZICEF |
93544
|
GLAXOSMITHKLINE HOLDINGS (AMERICAS) INC. |
H |
5 |
1 |
4 |
KX |
|
|
|
|
|
|
|
TAZICEF INJECTION |
93544
|
GLAXOSMITHKLINE HOLDINGS (AMERICAS) INC. |
H |
5 |
1 |
4 |
KX |
|
|
|
|
|
|
| MOEC |
SOS |
A A C |
R C |
S L C |
CIIC |
U P Q |
U S C |
Unit Price |
UI |
UICF |
MCD |
Action Date |
C/H |
| DA |
S9M |
H |
|
M |
U |
1 |
A |
$487.01 |
PG |
|
C2201X- |
Oct-01-1997 |
H |
| DF |
S9M |
H |
|
M |
U |
1 |
F |
$487.01 |
PG |
|
------- |
Oct-01-1997 |
H |
| DN |
S9M |
H |
|
M |
U |
1 |
N |
$487.01 |
PG |
|
9L----- |
Oct-01-1997 |
H |
| DS |
S9M |
H |
|
M |
U |
1 |
D |
$487.01 |
PG |
|
------- |
Oct-01-1997 |
H |
| MOEC |
PC |
Phrase |
QPA |
UOM |
OOU |
JTC |
| DA |
K |
U/I CONTAINS 10EA |
000 |
|
|
|
| DA |
R |
REFER TO EDI ITEM |
000 |
|
|
|
| DA |
R |
REFER TO NOT DMSB STZD |
000 |
|
|
|
| DF |
K |
U/I CONTAINS 10EA |
000 |
|
|
|
| DF |
R |
REFER TO EDI ITEM |
000 |
|
|
|
| DF |
R |
REFER TO NON-STD NON-DMSB REV |
000 |
|
|
|
| DN |
K |
U/I CONTAINS 10EA |
000 |
|
|
|
| DN |
R |
REFER TO EDI ITEM |
000 |
|
|
|
| DN |
R |
REFER TO NON-STD NON-DMSB REV |
000 |
|
|
|
| DS |
K |
U/I CONTAINS 10EA |
000 |
|
|
|
| DS |
R |
REFER TO EDI ITEM |
000 |
|
|
|
| DS |
R |
REFER TO NON-STD NON-DMSB REV |
000 |
|
|
|
Technical Characteristics Information
| MRC |
Requirement Statement |
Reply Statement |
| AGXW |
PHYSICAL FORM |
POWDER |
| AKJA |
ACTIVE MEDICAMENT MEDICINAL STRENGTH |
6.000 GRAMS CEFTAZIDIME, ANHYDROUS EQUIVALENT |
| CBBL |
FEATURES PROVIDED |
STERILE |
| CQCT |
PRIMARY CONTAINER TYPE |
VIAL, MULTIPLE DOSE |
| CRLK |
PRIMARY CONTAINER CONTENT QUANTITY |
6.000 GRAMS OF ACTIVE INGREDIENT |
| CSCW |
TOTAL PRIMARY CONTAINER QUANTITY |
10 |
| CSGS |
ADMINISTRATION |
INTRAVENOUS |
| FEAT |
SPECIAL FEATURES |
EACH VIAL CONTAINS CEFTAZIDIME PENTAHYDRATE EQUIVALENT TO 6 GRAMS OF CEFTAZIDIME,AND 118 MILLIGRAMS SODIUM CARBONATE PER GRAM OF CEFTAZIDIME; PHARMACY BULK VIAL |
| PKTY |
UNIT PACKAGE TYPE |
PACKAGE |
| MOE Rule |
Former MOER |
Effective |
AMC |
AMSC |
IMC |
IMCA |
Collaborators |
Receivers |
| A111 |
|
Aug-09-1991 |
3 |
Z |
|
|
|
|
| FSKX |
|
Aug-09-1991 |
3 |
Z |
|
|
|
|
| N9LM |
|
Aug-09-1991 |
3 |
Z |
|
|
|
|
|